Zobrazeno 1 - 6
of 6
pro vyhledávání: '"David Ernest Burgio"'
Publikováno v:
Osteoporosis International
Summary: Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-
Autor:
Ellen Matzkin, Jose R. Zanchetta, Pierre D. Delmas, John F. Beary, Claude-Laurent Benhamou, Christian Roux, Steven Boonen, Rachelle Eusebio, Z. Man, Artur J. Racewicz, Michael R. McClung, David Ernest Burgio
Publikováno v:
Osteoporosis International
Summary: This study showed that risedronate 150-mg once a month provides similar efficacy and safety at 2 years compared with risedronate 5-mg daily for the treatment of postmenopausal osteoporosis. This adds to the range of risedronate dosing option
Autor:
Lynn M. Darbie, Jacques P. Brown, Artur J. Racewicz, Ellen Matzkin, John F. Beary, David Ernest Burgio, Louis-Georges Ste-Marie
Publikováno v:
Clinical Therapeutics. 31:272-285
Risedronate 5 mg/d is approved by the US Food and Drug Administration for the treatment and prevention of postmenopausal osteoporosis. Once-monthly dosing options might increase treatment compliance and persistence.The aim of this study was to compar
Autor:
Christian Roux, Ellen Matzkin, Rachelle Eusebio, Claude-Laurent Benhamou, Michael R. McClung, Z. Man, John F. Beary, Artur J. Racewicz, Pierre D. Delmas, David Ernest Burgio, Jose R. Zanchetta, Steven Boonen
Publikováno v:
Bone. 42:36-42
Introduction: Risedronate has been shown to be effective in the treatment of postmenopausal osteoporosis when given orally in daily or weekly doses or on 2 consecutive days per month. This randomized, double-blind, multi-center study was designed to
Publikováno v:
Journal of Bone and Mineral Research. 20:2105-2115
The incidences of osteoporosis and renal insufficiency increase with age. We studied the influence of renal function on the safety and efficacy of risedronate 5 mg daily in osteoporotic women. Risedronate was safe and effective in osteoporotic women
Publikováno v:
Current medical research and opinion. 23(12)
Risedronate 5 mg daily significantly reduces the incidence of vertebral and non-vertebral osteoporotic fractures in postmenopausal women. We compared the efficacy and tolerability of risedronate 50 mg administered on 3 consecutive days per month, wit